HRP20180129T1 - Oralno raspadajuća čvrsta jedinica doze koja sadrži estetrol komponentu - Google Patents
Oralno raspadajuća čvrsta jedinica doze koja sadrži estetrol komponentu Download PDFInfo
- Publication number
- HRP20180129T1 HRP20180129T1 HRP20180129TT HRP20180129T HRP20180129T1 HR P20180129 T1 HRP20180129 T1 HR P20180129T1 HR P20180129T T HRP20180129T T HR P20180129TT HR P20180129 T HRP20180129 T HR P20180129T HR P20180129 T1 HRP20180129 T1 HR P20180129T1
- Authority
- HR
- Croatia
- Prior art keywords
- dosage unit
- solid dosage
- unit according
- solid
- estetrol
- Prior art date
Links
- 239000007787 solid Substances 0.000 title claims 18
- 229950009589 estetrol Drugs 0.000 title claims 9
- AJIPIJNNOJSSQC-NYLIRDPKSA-N estetrol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)[C@@H]4O)O)[C@@H]4[C@@H]3CCC2=C1 AJIPIJNNOJSSQC-NYLIRDPKSA-N 0.000 title claims 7
- 238000000034 method Methods 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 239000008187 granular material Substances 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 238000001816 cooling Methods 0.000 claims 3
- 239000007884 disintegrant Substances 0.000 claims 3
- 150000005846 sugar alcohols Chemical class 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- -1 estetrol ester Chemical class 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 239000004386 Erythritol Substances 0.000 claims 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 238000005336 cracking Methods 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 235000019414 erythritol Nutrition 0.000 claims 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 1
- 229940009714 erythritol Drugs 0.000 claims 1
- 238000002657 hormone replacement therapy Methods 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 239000000905 isomalt Substances 0.000 claims 1
- 235000010439 isomalt Nutrition 0.000 claims 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 239000000583 progesterone congener Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (17)
1. Oralno raspadajuća čvrsta farmaceutska jedinica doze koja ima težinu između 50 i 1,000 mg, naznačena time što se navedena jedinica doze sastoji od:
• 4-95 tež.% granula koje se sastoje od:
- 3-80 tež.% estetrol komponente izabrane od estetrola, estetrol estera i njihovih kombinacija;
- 20-97 tež.% C4-C12 šećernog alkohola;
- 0-45 tež.% jednog ili više drugih farmaceutski prihvatljivih sastojaka; i
• 5-96 tež.% jednog ili više farmaceutski prihvatljivih ekscipijensa.
pri čemu čvrsta jedinica doze sadrži najmanje 0.1 mg estetrol komponente.
2. Čvrsta jedinica doze prema patentnom zahtjevu 1, naznačena time što je estetrol komponenta estetrol, poželjno anhidridan estetrol.
3. Čvrsta jedinica doze prema patentnom zahtjevu 1 ili 2, naznačena time što granule predstavljaju između 5 i 90 tež. % jedinice doze.
4. Čvrsta jedinica doze prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što granule imaju srednju veličinu prema zapremini između 30 i 200 μm, poželjno između 40 i 150 μm.
5. Čvrsta jedinica doze prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što je C4-C12 šećerni alkohol izabran od manitola, eritritola, izomalta i njihovih kombinacija.
6. Čvrsta jedinica doze prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što jedan ili više farmaceutski prihvatljivih ekscipijensa sadrže najmanje 30% prema težini navedenog jednog ili više farmaceutski prihvatljivih ekscipijensa čestica koje sadrže sredstvo za raspadanje disperzirano u matriksu koji sadrži C4-C6 šećerni alkohol.
7. Čvrsta jedinica doze prema patentnom zahtjevu 6, naznačena time što čestice sadrže 10-50 tež. % sredstva za raspadanje i 40-90 tež. % C4-C6 šećernog alkohola.
8. Čvrsta jedinica doze prema patentnom zahtjevu 7, naznačena time što je sredstvo za raspadanje izabrano od krospovidona, hidroksipropil celuloze, kroskarmeloze natrija i kristalne celuloze i njihovih kombinacija.
9. Čvrsta jedinica doze prema bilo kojem od patentnih zahtjeva 6-8, naznačena time što je C4-C6 šećerni alkohol izabran od manitola, ksilitola i njihovih kombinacija.
10. Čvrsta jedinica doze prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što jedinica doze sadrži 0.05-10 mg progestogena.
11. Čvrsta jedinica doze prema bilo kojem od prethodnih patentnih zahtjeva za upotrebu u medicinskom liječenju ili za upotrebu u zamjenskoj hormonskoj terapiji kod žena, pri čemu navedena upotreba sadrži sublingualnu, bukalnu ili sublabijalnu primjenu jedinice doze.
12. Čvrsta jedinica doze za upotrebu prema patentnom zahtjevu 11, naznačena time što navedena upotreba sadrži primjenu jednom dnevno u tijeku perioda od najmanje 1 tjedna.
13. Postupak ženske kontracepcije, naznačen time što navedeni postupak sadrži subligualnu, bukalnu ili sublabijalnu primjenu jedinice doze prema bilo kojem od patentnih zahtjeva 1-10.
14. Postupak prema patentnom zahtjevu 13, naznačen time što navedeni postupak sadrži primjenu jednom dnevno u tijeku perioda od najmanje 1 tjedna.
15. Postupak za pripremu čvrste jedinice doze prema bilo kojem od patentnih zahtjeva 1-10, naznačen time što navedeni postupak sadrži korake:
• osiguravanje vrele smjese estetrol komponente koja se može pumpati, C4-C12 šećernog alkohola i izborno jednog ili više drugih farmaceutski prihvatljivih sastojaka, pri čemu navedena vrela smjesa koja se može pumpati ima temperaturu od najmanje 105°C;
• hlađenje vrele smjese koja se može pumpati da bi se stvrdnuo C4-C12 šećerni alkohol i razbijanje smjese koja se može pumpati prije ili poslije navedenog hlađenja da bi se proizvele čvrste granule;
• miješanje granula s jednim ili više farmaceutski prihvatljivih ekscipijensa; i
• formiranje smjese u čvrstu jedinicu doze.
16. Postupak prema patentnom zahtjevu 15, naznačen time što smjesa koja se može pumpati ima temperaturu od najmanje 160°C, poželjno od 180 do 240°C.
17. Postupak prema patentnom zahtjevu 15 ili 16, naznačen time što je vrela smjesa koja se može pumpati podvrgnuta hlađenju prskanjem da bi se proizvele čvrste granule.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13196904 | 2013-12-12 | ||
| PCT/EP2014/077127 WO2015086643A1 (en) | 2013-12-12 | 2014-12-10 | Orally disintegrating solid dosage unit containing an estetrol component |
| EP14814804.2A EP3079671B1 (en) | 2013-12-12 | 2014-12-10 | Orally disintegrating solid dosage unit containing an estetrol component |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180129T1 true HRP20180129T1 (hr) | 2018-02-23 |
Family
ID=49759137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180129TT HRP20180129T1 (hr) | 2013-12-12 | 2018-01-23 | Oralno raspadajuća čvrsta jedinica doze koja sadrži estetrol komponentu |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US9884064B2 (hr) |
| EP (1) | EP3079671B1 (hr) |
| JP (1) | JP6447931B2 (hr) |
| KR (1) | KR102265150B1 (hr) |
| CN (1) | CN105979935B (hr) |
| AU (1) | AU2014363599B2 (hr) |
| BR (1) | BR112016013502B1 (hr) |
| CA (1) | CA2932855C (hr) |
| CL (1) | CL2016001411A1 (hr) |
| CY (1) | CY1119817T1 (hr) |
| DK (1) | DK3079671T3 (hr) |
| EA (1) | EA032306B1 (hr) |
| ES (1) | ES2655076T3 (hr) |
| HR (1) | HRP20180129T1 (hr) |
| HU (1) | HUE035848T2 (hr) |
| IL (1) | IL246082B (hr) |
| LT (1) | LT3079671T (hr) |
| MA (1) | MA39105B1 (hr) |
| MX (1) | MX369035B (hr) |
| NO (1) | NO3079671T3 (hr) |
| NZ (1) | NZ720906A (hr) |
| PL (1) | PL3079671T3 (hr) |
| PT (1) | PT3079671T (hr) |
| RS (1) | RS56738B1 (hr) |
| SG (1) | SG11201604741UA (hr) |
| SI (1) | SI3079671T1 (hr) |
| TN (1) | TN2016000230A1 (hr) |
| WO (1) | WO2015086643A1 (hr) |
| ZA (1) | ZA201603903B (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101994805B1 (ko) | 2011-06-01 | 2019-07-01 | 에스테트라 에스.피.알.엘. | 에스테트롤 중간체의 제조 방법 |
| CN103619867B (zh) | 2011-06-01 | 2015-12-23 | 埃斯特拉公司 | 用于产生雌四醇中间体的方法 |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| DK2741824T3 (en) * | 2011-08-11 | 2017-07-10 | Estetra Sprl | Use of estetrol as emergency contraception |
| MD3310345T2 (ro) | 2015-06-18 | 2021-07-31 | Estetra Sprl | Comprimată orodispersabilă ce conține estetrol |
| MD3310346T2 (ro) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Comprimată orodispersabilă ce conține estetrol |
| EP3701944B1 (en) | 2015-06-18 | 2021-12-08 | Estetra SRL | Orodispersible dosage unit containing an estetrol component |
| NO3106148T3 (hr) * | 2015-06-18 | 2018-08-11 | ||
| CA3178291A1 (en) * | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| US20200046729A1 (en) * | 2016-08-05 | 2020-02-13 | Estetra Sprl | Methods using combined oral contraceptive compositions with reduced cardiovascular effects |
| JOP20200169A1 (ar) * | 2018-02-07 | 2020-07-07 | Estetra Sprl | تركيبة لمنع الحمل بتأثيرات منخفضة على القلب والأوعية |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| JOP20200260A1 (ar) * | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997004752A1 (en) * | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
| US6117446A (en) | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
| EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| DK1390040T3 (da) | 2001-05-18 | 2007-04-23 | Pantarhei Bioscience Bv | Farmaceutisk præparat til anvendelse i hormonerstatningsterapi |
| WO2002094279A1 (en) | 2001-05-23 | 2002-11-28 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahidroxilated estrogen for use in hormonal contraception |
| US7871995B2 (en) | 2001-05-23 | 2011-01-18 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
| WO2003018026A1 (en) | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
| ES2278925T3 (es) | 2001-11-15 | 2007-08-16 | Pantarhei Bioscience B.V. | Uso de compuestos estrogenicos en combinacion con compuestos progestogenicos en terapias de sustitucion hormonal. |
| MEP37208A (en) * | 2002-02-21 | 2011-02-10 | Bayer Schering Pharma Ag | Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12 |
| GB0410616D0 (en) | 2004-05-13 | 2004-06-16 | Unilever Plc | Antiperspirant or deodorant compositions |
| US20070048369A1 (en) | 2005-08-26 | 2007-03-01 | National Starch And Chemical Investment Holding Corporation | Mucosal delivery tablet |
| US20090221540A1 (en) | 2006-01-09 | 2009-09-03 | Pantarhei Bioscience B.V. | Method of Treating An Acute Vascular Disorder |
| CN101443015A (zh) * | 2006-06-08 | 2009-05-27 | 沃纳奇尔科特公司 | 具有改善的生物利用率的乙炔雌二醇及其药物前体的固体剂型的给药方法 |
| US20070286819A1 (en) | 2006-06-08 | 2007-12-13 | Warner Chilcott Company, Inc. | Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability |
| CA2670544A1 (en) * | 2006-11-29 | 2008-06-05 | Wyeth | Estrogen/ serm and estrogen/ progestin bi-layer tablets |
| US7867515B2 (en) * | 2006-12-20 | 2011-01-11 | TEVA Woman's Health, Inc. | Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof |
| EP2117518A2 (en) * | 2007-01-12 | 2009-11-18 | Wyeth a Corporation of the State of Delaware | Tablet-in-tablet compositions |
| WO2008156365A1 (en) * | 2007-06-21 | 2008-12-24 | Pantarhei Bioscience B.V. | Treatment of meconium aspiration syndrome with estrogens |
| WO2010033832A2 (en) | 2008-09-19 | 2010-03-25 | Evestra, Inc. | Estriol formulations |
| DE102009007771B4 (de) * | 2009-02-05 | 2012-02-16 | Bayer Schering Pharma Aktiengesellschaft | Bukkales Applikationssystem, 17α-Estradiol enthaltend |
| CN102058604A (zh) * | 2009-11-17 | 2011-05-18 | 北京万全阳光医学技术有限公司 | 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法 |
| WO2014159377A1 (en) | 2013-03-14 | 2014-10-02 | Teva Women's Health, Inc. | Compositions containing tanaproget and natural estrogens |
-
2014
- 2014-12-10 SI SI201430525T patent/SI3079671T1/en unknown
- 2014-12-10 TN TN2016000230A patent/TN2016000230A1/en unknown
- 2014-12-10 PL PL14814804T patent/PL3079671T3/pl unknown
- 2014-12-10 EP EP14814804.2A patent/EP3079671B1/en active Active
- 2014-12-10 NO NO14814804A patent/NO3079671T3/no unknown
- 2014-12-10 KR KR1020167018146A patent/KR102265150B1/ko active IP Right Grant
- 2014-12-10 ES ES14814804.2T patent/ES2655076T3/es active Active
- 2014-12-10 EA EA201691226A patent/EA032306B1/ru unknown
- 2014-12-10 WO PCT/EP2014/077127 patent/WO2015086643A1/en active Application Filing
- 2014-12-10 SG SG11201604741UA patent/SG11201604741UA/en unknown
- 2014-12-10 MX MX2016007595A patent/MX369035B/es active IP Right Grant
- 2014-12-10 JP JP2016539161A patent/JP6447931B2/ja active Active
- 2014-12-10 BR BR112016013502-4A patent/BR112016013502B1/pt not_active IP Right Cessation
- 2014-12-10 CA CA2932855A patent/CA2932855C/en active Active
- 2014-12-10 RS RS20180016A patent/RS56738B1/sr unknown
- 2014-12-10 HU HUE14814804A patent/HUE035848T2/en unknown
- 2014-12-10 AU AU2014363599A patent/AU2014363599B2/en active Active
- 2014-12-10 NZ NZ720906A patent/NZ720906A/en unknown
- 2014-12-10 PT PT148148042T patent/PT3079671T/pt unknown
- 2014-12-10 US US15/103,180 patent/US9884064B2/en active Active
- 2014-12-10 LT LTEP14814804.2T patent/LT3079671T/lt unknown
- 2014-12-10 DK DK14814804.2T patent/DK3079671T3/en active
- 2014-12-10 CN CN201480075244.4A patent/CN105979935B/zh active Active
- 2014-12-10 MA MA39105A patent/MA39105B1/fr unknown
-
2016
- 2016-06-07 IL IL246082A patent/IL246082B/en active IP Right Grant
- 2016-06-08 ZA ZA2016/03903A patent/ZA201603903B/en unknown
- 2016-06-08 CL CL2016001411A patent/CL2016001411A1/es unknown
-
2017
- 2017-12-22 US US15/852,187 patent/US9987287B2/en active Active
-
2018
- 2018-01-10 CY CY20181100031T patent/CY1119817T1/el unknown
- 2018-01-23 HR HRP20180129TT patent/HRP20180129T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180129T1 (hr) | Oralno raspadajuća čvrsta jedinica doze koja sadrži estetrol komponentu | |
| JP2016540021A5 (hr) | ||
| HRP20210555T1 (hr) | Orodisperzibilna tableta koja sadrži estetrol | |
| HRP20210668T1 (hr) | Orodisperzibilna tableta koja sadrži estetrol | |
| HRP20211968T1 (hr) | Orodisperzibilna jedinica za doziranje koja sadrži komponentu estetrola | |
| JP2018521985A5 (hr) | ||
| ES2646816T3 (es) | Composiciones de dosificaciones orales de liberación retardada que contienen CDDO-Me amorfo | |
| HRP20220332T1 (hr) | Farmaceutski pripravak koji sadrži drospirenon za uporabu kao kontraceptiv | |
| US20190336458A1 (en) | Eutectic formulations of cyclobenzaprine hydrochloride | |
| JP6446552B2 (ja) | 体重と体脂肪減少に用いられる組成物およびその医薬品と使用 | |
| JP2018517718A5 (hr) | ||
| HRP20180889T1 (hr) | Orodisperzibilna dozna jedinica koja sadrži estetrolsku komponentu | |
| AU2014299447B2 (en) | Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin | |
| ES2606307T3 (es) | Producto de co-micronización que comprende acetato de ulipristal | |
| SI2501234T1 (en) | METHODS AND INGREDIENTS FOR TREATMENT OF SYMPTOMS RELATED TO POST-TRAUMATIC STRESS EMISSIONS WITH THE USE OF CYCLOBENZAPRINE | |
| RU2015132902A (ru) | Новый быстрорастворимый состав гранул с улучшенной растворимостью | |
| RU2016117186A (ru) | Комбинированная композиция, содержащая тадалафил и амлодипин | |
| JP2021504479A5 (hr) | ||
| JP2015120758A5 (hr) | ||
| KR20080075113A (ko) | 에스시탈로프람 및 부프로피온을 함유하는 안정한 약학적제형 | |
| CN101991577A (zh) | 新型精神类药物组合物 | |
| RU2590978C1 (ru) | Капсулированный препарат для лечения простуды и способ его получения | |
| CN103110631B (zh) | 复方酚美麻敏缓释制剂及其制备方法 | |
| Shenoy et al. | Development and Evaluation of chronomodulated delivery system of metoclopramide hydrochloride | |
| HRP20221073T1 (hr) | Postupak pripreme postojanih formulacija mesalazina |